Pharming Group
PHAR
2 hedge funds and large institutions have $234K invested in Pharming Group in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
21% less capital invested
Capital invested by funds: $296K → $234K (-$61.2K)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$134K |
| 2 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$134K |
PHAR Hedge Fund Activity: Q4 2023 in Review
2 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q4 2023, worth a combined $234K — down 21% from $296K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHAR and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $3.44K. The largest seller was Brinker Capital Investments, exiting entirely with an estimated $134K sold.
- 2 institutional investors held Pharming Group (PHAR) as of Q4 2023, down from 3 in Q3 2023.
- Funds reported $234K of Pharming Group stock for Q4 2023, down 21% quarter-over-quarter.
- 1 fund opened new Pharming Group positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest Pharming Group buyer in Q4 2023 was Morgan Stanley, an estimated $3.44K added.
- The largest Pharming Group seller in Q4 2023 was Brinker Capital Investments, an estimated $134K sold.
Based on aggregated 13F filings for Q4 2023.